About PhagoMed
PhagoMed is a company based in Vienna (Austria) founded in 2016 by Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, and Andrej Trampuz was acquired by BioNTech in November 2021. PhagoMed has raised $1.7 million across 2 funding rounds from investors including BioNTech. PhagoMed operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Vienna, Austria
- Founders Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, Andrej Trampuz
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PhagoMed
PhagoMed has successfully raised a total of $1.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.7 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PhagoMed
PhagoMed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BioNTech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Immunotherapeutics for cancer and other diseases are developed.
|
Locked | Locked | Locked |
Investor details for PhagoMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PhagoMed
Investment portfolio details for PhagoMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PhagoMed
Detailed financials for PhagoMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phagomed Comparisons
Peer comparison for PhagoMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PhagoMed
PhagoMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of PhagoMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phagomed
Complete news archive for PhagoMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhagoMed
PhagoMed was founded in 2016 and raised its 1st funding round 2 years after it was founded.
PhagoMed is headquartered in Vienna, Austria.
PhagoMed is a funded company, having raised a total of $1.7M across 2 funding rounds to date.
PhagoMed is a developing a phage drug development platform through which they are advancing a portfolio of candidates currently at the preclinical stage. The company claims that phage therapy is a better alternative to antibiotics due to the issue of resistance, their insufficient effectiveness against biofilms and also due to their side effects. In exceptional and severe cases the company is exploring experimental treatment options as per the Helsinki protocol for wound and periprosthetic infections. The company is looking for partners to establish preclinical proof of their technology.
PhagoMed's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
PhagoMed has 1 investor. Key investors include BioNTech.